New book by Larry Connors Click here Improve your trading - See how
Targeted at the health and beauty consumer market, the Striking(TM) Skin Care line features a core ritual of daily essentials including Multi-Vitamin Creme Cleanser, Multi-Peptide Serum, Rejuvenating Eye Creme and Restorative Moisture Creme. The serum, moisturizer and eye cream are formulated with Helix BioMedix's patented SmartPeptides(TM) technology. With over 15 years of research and development devoted to regulating cellular processes, Helix BioMedix has elevated peptide science to a new level of precise, bioactive peptides that function to address specific, targeted skin care concerns.
"Our SmartPeptides(TM) technology stimulates the skin's own natural repair process and helps defend against environmental stress," said R. Stephen Beatty, President and CEO of Helix BioMedix. "Tests have shown that SmartPeptides(TM) boost collagen production and support the skin's extracellular matrix, thereby reducing the appearance of fine lines and wrinkles while increasing the overall firmness of the skin."
The products will initially be distributed via catalog and online through Gold Violin (www.goldviolin.com) and Norm Thompson (www.normthompson.com). Both companies are owned by Orchard Brands, a company with over $1 billion in revenue that specializes in the over-55 consumer market.
Additional Updates
DermaVenture, LLC recently won the prestigious Electronic Retailing Association's ERA Award for the Best U.S. Hispanic Long Form Show (infomercial) of the year. The show features the innovative P.A.C. Perfect(TM) three step acne control product line jointly developed by DermaVentures and Helix BioMedix. The clinically proven system uses Oligopeptide-10 from Helix BioMedix, combined with salicylic acid for effective treatment of acne breakouts. The P.A.C. Perfect(TM) system works to calm breakouts, reduce irritation and support acne recovery for a clear and more radiant appearance. It treats acne symptoms at their core, and then continues to help control future breakouts while reducing the appearance of troublesome red spots. More information on the products can be found at www.dermaventures.com.
Also, Helix BioMedix's licensee, Evonik, a division of Goldschmidt GmbH, recently presented data at the International Federation of Societies of Cosmetic Chemists (IFSCC) Congress in Barcelona, Spain. The 60 subject study showed an increased expression of ECM-synthesizing enzymes including hyaluronic acid synthase, as well as expression and production of ECM proteins like collagen and fibronectin with topical application of H14. Launching its first Helix BioMedix peptide under the trade name Tego(R) Pep 4-17, Evonik is working on additional Helix BioMedix peptides through its own research and in collaboration with leading universities. A summary poster may be found at http://www.helixbiomedix.com/wt/page/presentations.
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.
Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners. Striking and SmartPeptides are trademarks of Helix BioMedix, Inc. P.A.C. Perfect is a trademark of DermaVentures, LLC. Tego is a registered trademark of Evonik Goldschmidt GmbH.
More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.
Forward-Looking Statements
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Helix BioMedix, Inc.
Shelton Group Investor Relations Ryan Bright, 972-239-5119 X 159 rbright@sheltongroup.com or Helix BioMedix, Inc. R. Stephen Beatty, 425-402-8400 President and CEO sbeatty@helixbiomedix.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
